No price history available.
Key financial summary
Financials in IDR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | IDRm | 7,110,124 | 9,381,891 | 9,518,012 | 11,190,511 | 12,207,563 | 12,847,434 | N/A | N/A |
| Operating profit | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | IDRm | 116,163 | 674,117 | 696,495 | 1,211,283 | 902,152 | 1,112,663 | N/A | N/A |
| EPS reported | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in IDR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
PT Siloam International Hospitals Tbk operates hospitals and clinics in Indonesia. The company offers general, pre-marital, and lite checkups; male and female screenings; heart, kidney, and cancer screenings; visa application and preemployment screenings; and vaccine and genomic testing services. It also provides diagnostic services, including laboratory and radiology checks; home services; COVID-19 tests; radiation therapy; and teleconsultation services. In addition, it offers services in the areas of andrology, anesthesiology, and arrythmia; cardiothoracic, digestive, general, neuro, pediatric, plastic, and vascular surgery; cardiology, cardiovascular emergency and intensive care, cardiovascular imaging, pediatric cardiology and congenital heart diseases, and preventive cardiology and cardiac rehabilitation; clinical nutrition and psychology; medical acupuncture and laboratory; dermatology, venereology, and aesthetics; and echocardiography, internal medicine, interventional cardiology, neurology, nuclear medicine, obstetrics and gynecologist, occupational medicine, ophthalmology, orthopedic and traumatology, otorhinolaryngology, physical medicine and rehabilitation, pulmonology, radiation oncology, radiology, sports medicine, and urology. Further, it engages in trading, development, mining, agriculture, land transportation, printing, plantation, forestry, electrical, mechanical, engineering, construction, and real estate businesses; computer programming; software publishing and retail trading; provision of management consulting, retail, professional, and scientific and technical; web portal and/or digital platform business; workshops; leasing; wholesale trade; IT; and social services. The company was formerly known as PT Sentralindo Wirasta. PT Siloam International Hospitals Tbk was founded in 1996 and is headquartered in Tangerang, Indonesia. PT Siloam International Hospitals Tbk operates as a subsidiary of Sight Investment Company Pte. Limited.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
PT Siloam International Hospitals Tbk (SILO.JK)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
PT Siloam International Hospitals Tbk operates hospitals and clinics in Indonesia. The company offers general, pre-marital, and lite checkups; male and female screenings; heart, kidney, and cancer screenings; visa application and preemployment screenings; and vaccine and genomic testing services. It also provides diagnostic services, including laboratory and radiology checks; home services; COVID-19 tests; radiation therapy; and teleconsultation services. In addition, it offers services in the areas of andrology, anesthesiology, and arrythmia; cardiothoracic, digestive, general, neuro, pediatric, plastic, and vascular surgery; cardiology, cardiovascular emergency and intensive care, cardiovascular imaging, pediatric cardiology and congenital heart diseases, and preventive cardiology and cardiac rehabilitation; clinical nutrition and psychology; medical acupuncture and laboratory; dermatology, venereology, and aesthetics; and echocardiography, internal medicine, interventional cardiology, neurology, nuclear medicine, obstetrics and gynecologist, occupational medicine, ophthalmology, orthopedic and traumatology, otorhinolaryngology, physical medicine and rehabilitation, pulmonology, radiation oncology, radiology, sports medicine, and urology. Further, it engages in trading, development, mining, agriculture, land transportation, printing, plantation, forestry, electrical, mechanical, engineering, construction, and real estate businesses; computer programming; software publishing and retail trading; provision of management consulting, retail, professional, and scientific and technical; web portal and/or digital platform business; workshops; leasing; wholesale trade; IT; and social services. The company was formerly known as PT Sentralindo Wirasta. PT Siloam International Hospitals Tbk was founded in 1996 and is headquartered in Tangerang, Indonesia. PT Siloam International Hospitals Tbk operates as a subsidiary of Sight Investment Company Pte. Limited.